Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Cited by (1,079)

Items 101–200 of 1,079

1. Strategies to improve radiotherapy with targeted drugs
   Adrian C. Begg, Fiona A. Stewart, Conchita Vens · 2011 · Nature reviews. Cancer
2. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
   Shiqing Li, Karl R. Schmitz, Philip D. Jeffrey, Jed J. W. Wiltzius, Paul H. Kussie, Kathryn M. Ferguson · 2005 · Cancer Cell
3. Advances in understanding cancer genomes through second-generation sequencing
   Matthew M. Meyerson, Stacey Gabriel, Gad A. Getz · 2010 · Nature Reviews Genetics
4. Characterizing the cancer genome in lung adenocarcinoma
   Weir, Barbara A., Woo, Michele S., Getz, Gad, Perner, Sven, Ding, Li, Beroukhim, Rameen, Lin, William M., Province, Michael A., Kraja, Aldi, Johnson, Laura A. et al. · 2007 · Nature
5. Single-molecule and single-nanoparticle SERS: from fundamental mechanisms to biomedical applications
   X.-M. Qian, Shuming Nie · 2008 · Chemical Society Reviews
6. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
   M. Rivera, A. Mehta, M. Wahidi · 2013 · Chest
7. Circulating tumor cells: approaches to isolation and characterization
   Min Yu, Shannon L. Stott, Mehmet Toner, Shyamala Maheswaran, Daniel A. Haber · 2011 · The Journal of Cell Biology
8. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets
   Priscilla Kaliopi Brastianos, Scott L. Carter, Sandro Santagata, Daniel P. Cahill, Amaro N Taylor-Weiner, Robert T. Jones, Eliezer M. Van Allen, Michael S. Lawrence, Peleg Moshe Horowitz, Kristian Cibulskis et al. · 2015 · Cancer Discovery
9. Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
   Pao, William, Chmielecki, Juliann · 2010 · Nature Reviews Cancer
10. Kinase drug discovery 20 years after imatinib: progress and future directions
    Philip Cohen, Darren A.E. Cross, Pasi Antero Janne · 2021 · Nature Reviews Drug Discovery
11. Determinants of Tumor Response and Survival With Erlotinib in Patients With Non—Small-Cell Lung Cancer
    Roman Perez-Soler, Abraham Chachoua, Lisa A. Hammond, Eric Keith Rowinsky, Mark S. Huberman, Daniel D. Karp, James R. Rigas, Gary M. Clark, Pedro Santabarbara, Philip Bonomi · 2004 · Journal of Clinical Oncology
12. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
    Skoulidis, Ferdinandos, Heymach, John V. · 2019 · Nature Reviews Cancer
13. The quest to overcome resistance to EGFR-targeted therapies in cancer
    Curtis Robert Chong, Pasi Antero Janne · 2013 · Nature Medicine
14. ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
    Arteaga, Carlos L., Engelman, Jeffrey A. · 2014 · Cancer Cell
15. The Next-Generation Sequencing Revolution and Its Impact on Genomics
    Daniel C. Koboldt, Karyn Meltz Steinberg, David E. Larson, Richard K. Wilson, Elaine R. Mardis · 2013 · Cell
16. Whole-genome analysis informs breast cancer response to aromatase inhibition
    Matthew J. Ellis, Li Ding, Dong Shen, Jingqin Rosy Luo, Vera Jean Suman, John W. Wallis, Brian Andrew Van Tine, Jeremy Hoog, Reece Goiffon, Theodore C. Goldstein et al. · 2012 · Nature
17. Lung cancer: Biology and treatment options
    Hassan Lemjabbar‐Alaoui, Omer Ul Hassan, Yiwei Yang, Petra C. Buchanan · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
18. Role of Tyrosine Kinase Inhibitors in Cancer Therapy
    Amit Arora, Eric M. Scholar · 2005 · Journal of Pharmacology and Experimental Therapeutics
19. Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
    Nikhil Wagle, Caroline Emery, Michael F. Berger, Matthew J. Davis, Allison M. Sawyer, Panisa Pochanard, Sarah M. Kehoe, Cory M. Johannessen, Laura E. MacConaill, William C. Hahn et al. · 2011 · Journal of Clinical Oncology
20. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
    Yang, James C-H, Sequist, Lecia V, Geater, Sarayut Lucien, Tsai, Chun-Ming, Mok, Tony Shu Kam, Schuler, Martin, Yamamoto, Nobuyuki, Yu, Chong-Jen, Ou, Sai-Hong I, Zhou, Caicun et al. · 2015 · The Lancet Oncology
21. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors
    Gazdar, A F · 2009 · Oncogene
22. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
    Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio, Didier Debieuvre, Jean Mosser, H. Léna, L’Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, Virginie Westeel et al. · 2016 · The Lancet
23. The ERBB network: at last, cancer therapy meets systems biology
    Yosef Yarden, Gur Pines · 2012 · Nature reviews. Cancer
24. ErbB receptors and signaling pathways in cancer
    Hynes, Nancy E, MacDonald, Gwen · 2009 · Current Opinion in Cell Biology
25. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
    Isabel M. Chu, Ludger Hengst, Joyce M. Slingerland · 2008 · Nature reviews. Cancer
26. High-throughput oncogene mutation profiling in human cancer
    Roman Kurt Thomas, Alissa C. Baker, Ralph M. Debiasi, Wendy Winckler, Thomas LaFramboise, William M. Lin, Meng Wang, Whei Feng, Thomas Zander, Laura E. MacConaill et al. · 2007 · Nature Genetics
27. Understanding and targeting resistance mechanisms in NSCLC
    Julia K. Rotow, Trever Grant Bivona · 2017 · Nature reviews. Cancer
28. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
    Zhongwu Lai, Aleksandra A. Markovets, Miika J. Ahdesmaki, Brad Chapman, Oliver Hofmann, Robert K. McEwen, Justin Johnson, Brian Andrew Dougherty, J. Carl Barrett, Jonathan R. Dry · 2016 · Nucleic Acids Research
29. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial
    Maughan, Timothy S, Adams, Richard A, Smith, Christopher G, Meade, Angela M, Seymour, Matthew T, Wilson, Richard H, Idziaszczyk, Shelley, Harris, Rebecca, Fisher, David, Kenny, Sarah L et al. · 2011 · The Lancet
30. Lung cancer in never smokers – A review
    S. Couraud, Gérard Zalcman, Bernard J. Milleron, Franck Morin, Pierre-Jean Souquet · 2012 · European Journal of Cancer
31. The MAPK pathway across different malignancies: A new perspective
    Mauricio Burotto, Victoria L. Chiou, Jung‐Min Lee, Elise C. Kohn · 2014 · Cancer
32. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
    Eunice Lee Kwak, Raffaella Sordella, Daphne W. Bell, Nadia Godin-Heymann, Ross A. Okimoto, Brian W. Brannigan, Patricia L. Harris, David R. Driscoll, Panos M. Fidias, Thomas James Lynch et al. · 2005 · Proceedings of the National Academy of Sciences
33. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study
    Moroni, Mauro, Veronese, Silvio, Benvenuti, Silvia, Marrapese, Giovanna, Sartore-Bianchi, Andrea, Di Nicolantonio, Federica, Gambacorta, Marcello, Siena, Salvatore, Bardelli, Alberto · 2005 · The Lancet Oncology
34. EGFR Mutations and Lung Cancer
    Gilda da Cunha Santos, Frances A. Shepherd, Ming‐Sound Tsao · 2011 · Annual Review of Pathology Mechanisms of Disease
35. Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence
    Tetsuya Mitsudomi, Takayuki Kosaka, Hideki Endoh, Yoshitsugu Horio, Toyoaki Hida, Shoichi Mori, Shunzo Hatooka, Masayuki Shinoda, Takashi Takahashi, Yasushi Yatabe · 2005 · Journal of Clinical Oncology
36. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach
    Zender, Lars, Spector, Mona S., Xue, Wen, Flemming, Peer, Cordon-Cardo, Carlos, Silke, John, Fan, Sheung-Tat, Luk, John M., Wigler, Michael, Hannon, Gregory J. et al. · 2006 · Cell
37. Current Challenges in Cancer Treatment
    Jon Zugazagoitia, Cristiano Guedes, Santiago Ponce, Irene Ferrer, Sonia Molina‐Pinelo, Luis G Paz-Ares · 2016 · Clinical Therapeutics
38. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors
    Yong Jia, Cai‐Hong Yun, Eunyoung Park, Dalia Ercan, Mari Manuia, Jose Juarez, Chunxiao Xu, Kevin Rhee, Ting Chen, Haikuo Zhang et al. · 2016 · Nature
39. Targeting the EGFR signaling pathway in cancer therapy
    Parthasarathy Seshacharyulu, Moorthy Palanimuthu Ponnusamy, Dhanya Haridas, Maneesh Jain, Apar Kishor Ganti, Surinder K. Batra · 2012 · Expert Opinion on Therapeutic Targets
40. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
    Rita Nahta, Dihua Yu, Mien‐Chie Hung, Gabriel N. Hortobágyi, Francisco J. Esteva · 2006 · Nature Clinical Practice Oncology
41. American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
    Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel et al. · 2009 · Journal of Clinical Oncology
42. Awakening guardian angels: drugging the p53 pathway
    Brown, Christopher J., Lain, Sonia, Verma, Chandra S., Fersht, Alan R., Lane, David P. · 2009 · Nature Reviews Cancer
43. Transcriptome sequencing to detect gene fusions in cancer
    Christopher A. Maher, Chandan Kumar‐Sinha, Xuhong Cao, Shanker Kalyana Sundaram, Bo Han, Xiaojun Jing, Lee T. Sam, Terrence R. Barrette, Nallasivam Palanisamy, Arul M. Chinnaiyan · 2009 · Nature
44. Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines
    Paul Geeleher, Nancy Jean Cox, R. Stephanie Huang · 2014 · Genome biology
45. The BATTLE Trial: Personalizing Therapy for Lung Cancer
    Edward S. Kim, Roy S. Herbst, Ignacio Ivan Wistuba, J. Jack Lee, George R. Blumenschein, Anne S. Tsao, David J. Stewart, Marshall E. Hicks, Jeremy J. Erasmus, Sanjay Kumar Gupta et al. · 2011 · Cancer Discovery
46. Triple-negative breast cancer: therapeutic options
    Susan Jane Cleator, Wolfgang Heller, R. Charles Coombes · 2007 · The Lancet Oncology
47. Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
    Solca, Flavio, Dahl, Goeran, Zoephel, Andreas, Bader, Gerd, Sanderson, Michael, Klein, Christian, Kraemer, Oliver, Himmelsbach, Frank, Haaksma, Eric, Adolf, Guenther R. · 2012 · The Journal of Pharmacology and Experimental Therapeutics
48. Phase III Study of Erlotinib in Combination With Cisplatin and Gemcitabine in Advanced Non–Small-Cell Lung Cancer: The Tarceva Lung Cancer Investigation Trial
    Ulrich Gatzemeier, Anna Pluzanska, Aleksandra Szczęsna, Eckhard Kaukel, Jaromı́r Roubec, Flavio De Rosa, Janusz Milanowski, Hanna Karnicka-Mlodkowski, Miloš Pešek, Piotr Serwatowski et al. · 2007 · Journal of Clinical Oncology
49. Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Ron Bose, Shyam M. Kavuri, Adam C. Searleman, Wei Shen, Dong Shen, Daniel C. Koboldt, John D. Monsey, Nicholas J. Goel, Adam B. Aronson, Shunqiang Li et al. · 2012 · Cancer Discovery
50. Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma
    Gillette, Michael A., Satpathy, Shankha, Cao, Song, Dhanasekaran, Saravana M., Vasaikar, Suhas V., Krug, Karsten, Petralia, Francesca, Li, Yize, Liang, Wen-Wei, Reva, Boris et al. · 2020 · Cell
51. First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic <i>EGFR</i> Mutations
    Sequist, Lecia V., Martins, Renato G., Spigel, David, Grunberg, Steven M., Spira, Alexander, Jänne, Pasi A., Joshi, Victoria A., McCollum, David, Evans, Tracey L., Muzikansky, Alona et al. · 2008 · Journal of Clinical Oncology
52. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
    Joaquı́n Mateo, Debyani Chakravarty, Rodrigo Dienstmann, S. Jezdic, Abel González-Pérez, Núria López-Bigas, Charlotte K.Y. Ng, Philippe Lucien Bedard, Giampaolo Tortora, J.-Y. Douillard et al. · 2018 · Annals of Oncology
53. Tumour-targeting bacteria engineered to fight cancer
    Zhou, Shibin, Gravekamp, Claudia, Bermudes, David, Liu, Ke · 2018 · Nature Reviews Cancer
54. Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors
    Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Romel Somwar, Allan R. Li, Maureen Frances Zakowski, Anne C. Chiang, Guangli Yang, Ouathek Ouerfelli, Mark G. Kris et al. · 2006 · Clinical Cancer Research
55. Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
    Jonathan M. Weiss, Martin L. Sos, Danila Seidel, Martin Peifer, Thomas Zander, Johannes M. Heuckmann, Roland Tillmann Ullrich, Roopika Menon, Sebastian H. Maier, Alex Soltermann et al. · 2010 · Science Translational Medicine
56. Trends in kinase drug discovery: targets, indications and inhibitor design
    Misty M. Attwood, Doriano Fabbro, Aleksandr V. Sokolov, Stefan Knapp, Helgi B. Schiöth · 2021 · Nature Reviews Drug Discovery
57. Advances in covalent drug discovery
    Boike, Lydia, Henning, Nathaniel J., Nomura, Daniel K. · 2022 · Nature Reviews Drug Discovery
58. Role of epidermal growth factor receptor in breast cancer
    Hiroko Masuda, Dongwei Zhang, Chandra Bartholomeusz, Hiroyoshi Doihara, Gabriel N. Hortobágyi, Naoto Tada Ueno · 2012 · Breast Cancer Research and Treatment
59. Comparing antibody and small-molecule therapies for cancer
    Kohzoh Imai, Akinori Takaoka · 2006 · Nature reviews. Cancer
60. Intragenic ERBB2 kinase mutations in tumours
    Stephens, Philip, Hunter, Chris, Bignell, Graham, Edkins, Sarah, Davies, Helen, Teague, Jon, Stevens, Claire, O'Meara, Sarah, Smith, Raffaella, Parker, Adrian et al. · 2004 · Nature
61. Oncogenic PI3K deregulates transcription and translation
    Andreas G. Bader, Sohye Kang, Li Zhao, Peter K. Vogt · 2005 · Nature reviews. Cancer
62. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
    Jackman, David, Pao, William, Riely, Gregory J., Engelman, Jeffrey A., Kris, Mark G., Jänne, Pasi A., Lynch, Thomas, Johnson, Bruce E., Miller, Vincent A. · 2010 · Journal of Clinical Oncology
63. EGFR Mutations in Non–Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment
    Antonio Marchetti, Carla Martella, Lara Felicioni, Fabio Barassi, Simona Salvatore, Antonio Chella, Pierpaolo Camplese, Teodorico Iarussi, Felice Mucilli, Andrea Mezzetti et al. · 2005 · Journal of Clinical Oncology
64. Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer
    Shang‐Gin Wu, Jin‐Yuan Shih · 2018 · Molecular Cancer
65. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
    Aaron C. Tan, Daniel S.W. Tan · 2022 · Journal of Clinical Oncology
66. Activating mutations in ALK provide a therapeutic target in neuroblastoma
    George, Rani E., Sanda, Takaomi, Hanna, Megan, Fröhling, Stefan, II, William Luther, Zhang, Jianming, Ahn, Yebin, Zhou, Wenjun, London, Wendy B., McGrady, Patrick et al. · 2008 · Nature
67. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib
    Sae‐Won Han, Tae‐You Kim, Pil Gyu Hwang, Soohyun Jeong, Jeongmi Kim, In Sil Choi, Do‐Youn Oh, Jee Hyun Kim, Dong‐Wan Kim, Doo Hyun Chung et al. · 2005 · Journal of Clinical Oncology
68. The epidermal growth factor receptor family: Biology driving targeted therapeutics
    Matthew Joseph Wieduwilt, Mark M. Moasser · 2008 · Cellular and Molecular Life Sciences
69. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
    Seto, Takashi, Kato, Terufumi, Nishio, Makoto, Goto, Koichi, Atagi, Shinji, Hosomi, Yukio, Yamamoto, Noboru, Hida, Toyoaki, Maemondo, Makoto, Nakagawa, Kazuhiko et al. · 2014 · The Lancet Oncology
70. Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
    Bardelli, Alberto, Siena, Salvatore · 2010 · Journal of Clinical Oncology
71. Epidermal Growth Factor Receptor Biology in Head and Neck Cancer
    Shailaja Kalyankrishna, Jennifer Rubin Grandis · 2006 · Journal of Clinical Oncology
72. Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
    Linardou, Helena, Dahabreh, Issa J, Kanaloupiti, Dimitra, Siannis, Fotios, Bafaloukos, Dimitrios, Kosmidis, Paris, Papadimitriou, Christos A, Murray, Samuel · 2008 · The Lancet Oncology
73. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
    Han, Ji-Youn, Park, Keunchil, Kim, Sang-We, Lee, Dae Ho, Kim, Hyae Young, Kim, Heung Tae, Ahn, Myung Ju, Yun, Tak, Ahn, Jin Seok, Suh, Cheolwon et al. · 2012 · Journal of Clinical Oncology
74. Non–Small Cell Lung Cancer
    _ _ · 2008 · Journal of the National Comprehensive Cancer Network
75. Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib
    Gregory J. Riely, William J. Pao, DuyKhanh P. Ceppa, Allan R. Li, Naiyer A. Rizvi, Ennapadam S. Venkatraman, Maureen Frances Zakowski, Mark G. Kris, Marc Ladanyi, Vincent A. Miller · 2006 · Clinical Cancer Research
76. Nanomedicine therapeutic approaches to overcome cancer drug resistance
    Markman, Janet L., Rekechenetskiy, Arthur, Holler, Eggehard, Ljubimova, Julia Y. · 2013 · Advanced Drug Delivery Reviews
77. Non–Small Cell Lung Cancer
    David S. Ettinger, Wallace Akerley, Gerold Bepler, Matthew G. Blum, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas Anthony D’Amico, Todd L. Demmy, Apar Kishor Ganti et al. · 2010 · Journal of the National Comprehensive Cancer Network
78. Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
    Martin Reck, Klaus Friedrich Rabe · 2017 · New England Journal of Medicine
79. PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib
    Engelman, Jeffrey A., Zejnullahu, Kreshnik, Gale, Christopher-Michael, Lifshits, Eugene, Gonzales, Andrea J., Shimamura, Takeshi, Zhao, Feng, Vincent, Patrick W., Naumov, George N., Bradner, James E. et al. · 2007 · Cancer Research
80. Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer
    Jose M Baselga, Carlos L. Arteaga · 2005 · Journal of Clinical Oncology
81. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future.
    2015 · Europe PMC (PubMed Central)
82. Management of non-small-cell lung cancer: recent developments
    Martin Reck, David Felix Heigener, Tony S.K. Mok, Jean‐Charles Soria, Klaus Friedrich Rabe · 2013 · The Lancet
83. Glioblastoma: pathology, molecular mechanisms and markers
    Aldape, Kenneth, Zadeh, Gelareh, Mansouri, Sheila, Reifenberger, Guido, von Deimling, Andreas · 2015 · Acta Neuropathologica
84. <i>HER2</i> Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in <i>EGFR</i> -Mutant Lung Cancers That Lack the Second-Site <i>EGFR</i> T790M Mutation
    Takezawa, Ken, Pirazzoli, Valentina, Arcila, Maria E., Nebhan, Caroline A., Song, Xiaoling, de Stanchina, Elisa, Ohashi, Kadoaki, Janjigian, Yelena Y., Spitzler, Paula J., Melnick, Mary Ann et al. · 2012 · Cancer Discovery
85. Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
    I. Bernard Weinstein, Andrew K. Joe · 2006 · Nature Clinical Practice Oncology
86. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer
    Hirsch, Fred R., Varella-Garcia, Marileila, Bunn, Paul A., Franklin, Wilbur A., Dziadziuszko, Rafal, Thatcher, Nick, Chang, Alex, Parikh, Purvish, Pereira, José Rodrigues, Ciuleanu, Tudor et al. · 2006 · Journal of Clinical Oncology
87. Lung Cancer in Never Smokers: A Review
    Janakiraman Subramanian, Ramaswamy Govindan · 2007 · Journal of Clinical Oncology
88. Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
    Jeffrey A. Engelman, Pasi Antero Janne · 2008 · Clinical Cancer Research
89. Epidermal Growth Factor Receptor Targeting in Cancer
    John M. Mendelsohn, Jose M Baselga · 2006 · Seminars in Oncology
90. Epidermal Growth Factor Receptor Gene Mutations and Increased Copy Numbers Predict Gefitinib Sensitivity in Patients With Recurrent Non–Small-Cell Lung Cancer
    Toshimi Takano, Yuichiro Ohe, Hiromi Sakamoto, Koji Tsuta, Yoshihiro Matsuno, Ukihide Tateishi, Seiichiro Yamamoto, Hiroshi Nokihara, Noboru Yamamoto, Ikuo Sekine et al. · 2005 · Journal of Clinical Oncology
91. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression
    Mark Magdi Awad, Geoffrey R. Oxnard, David Michael Jackman, Daniel O. Savukoski, Dimity Hall, Priyanka Shivdasani, Jennifer C. Heng, Suzanne Eleanor Dahlberg, Pasi Antero Janne, Suman Verma et al. · 2016 · Journal of Clinical Oncology
92. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors
    Westover, D., Zugazagoitia, J., Cho, B.C., Lovly, C.M., Paz-Ares, L. · 2018 · Annals of Oncology
93. Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
    Paul K. Paik, Maria E. Arcila, Michael G. Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely · 2011 · Journal of Clinical Oncology
94. Understanding resistance to EGFR inhibitors—impact on future treatment strategies
    Wheeler, Deric L., Dunn, Emily F., Harari, Paul M. · 2010 · Nature Reviews Clinical Oncology
95. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
    Min Yuan, Lili Huang, Jianhua Chen, Jie Wu, Qing Xu · 2019 · Signal Transduction and Targeted Therapy
96. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer
    Nasser H. Hanna, Paul A. Bunn, Corey Jay Langer, Lawrence H. Einhorn, Troy H. Guthrie, Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark E. Morrison et al. · 2006 · Journal of Clinical Oncology
97. Somatic Mutations of the <i>HER2</i> Kinase Domain in Lung Adenocarcinomas
    Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi et al. · 2005 · Cancer Research
98. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants
    Greulich, Heidi, Chen, Tzu-Hsiu, Feng, Whei, Jänne, Pasi A, Alvarez, James V, Zappaterra, Mauro, Bulmer, Sara E, Frank, David A, Hahn, William C, Sellers, William R et al. · 2005 · PLoS Medicine
99. Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
    Scott J. Rodig, Mari A. Mino-Kenudson, Sanja Đačić, Beow Yong Yeap, Alice Tsang Shaw, Justine A. Barletta, Hannah Stubbs, Kenny Law, Neal Ian Lindeman, Eugene Jerome Mark et al. · 2009 · Clinical Cancer Research
100. Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
     Day, Chi-Ping, Merlino, Glenn, Van Dyke, Terry · 2015 · Cell